DEPO-PROVERA (medroxyprogesterone acetate)
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
June 2016
ADVERSE REACTIONS
General Disorders and Administration Site Condition: (addition to this section)
injection site...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts
More News: Drugs & Pharmacology | Medroxyprogesterone